Boston Scientific PT Raised to $20.00 at RBC Capital (BSX)
Posted on April 21, 2015 by John Miller in Analyst Articles - US, Investing
Boston Scientific logoAnalysts at RBC Capital raised their target price on shares of Boston Scientific (NYSE:BSX) from $17.00 to $20.00 in a research report issued to clients and investors on Monday. The firm currently has an “outperform” rating on the stock. RBC Capital’s price objective indicates a potential upside of 9.95% from the company’s current price.
A number of other analysts have also recently weighed in on BSX. Analysts at Argus reiterated a “hold” rating on shares of Boston Scientific in a research note on Monday, March 30th. Analysts at Barclays raised their price target on shares of Boston Scientific from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Monday, March 23rd. Analysts at Raymond James initiated coverage on shares of Boston Scientific in a research note on Friday, March 20th. They set an “outperform” rating and a $21.00 price target on the stock. Finally, analysts at Deutsche Bank reiterated a “hold” rating and set a $17.00 price target on shares of Boston Scientific in a research note on Thursday, March 19th. Ten equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Boston Scientific presently has an average rating of “Buy” and a consensus target price of $17.70.
Boston Scientific (NYSE:BSX) opened at 18.19 on Monday. Boston Scientific has a 52-week low of $11.10 and a 52-week high of $18.43. The stock has a 50-day moving average of $17. and a 200-day moving average of $14.. The company’s market cap is $24.20 billion.
Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $0.22 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.21 by $0.01. The company had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.91 billion. During the same quarter last year, the company posted $0.21 earnings per share. Boston Scientific’s revenue was up 2.7% compared to the same quarter last year. Analysts expect that Boston Scientific will post $0.91 EPS for the current fiscal year.
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women’s Health, Neuromodulation, and Electrophysiology.
